This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Davis, T. Articles by deFazio, A. Search for Related Content PubMed PubMed Citation Articles by Davis, T. Articles by deFazio, A.

Histone Deacetylase Inhibitors Decrease Proliferation and Modulate Cell Cycle Gene Expression in Normal Mammary Epithelial Cells¹

Department of Gynaecological Oncology [T. D., C. K., Y-E. C., A. deF.], Westmead Hospital, and Department of Obstetrics and Gynaecology [A. deF.] and Westmead Institute for Cancer Research [T. D., C. K., Y-E. C., C. L. C., A. deF.], University of Sydney, Westmead Hospital, Westmead, NSW 2145, Australia

ABSTRACT

Full-term pregnancy early in reproductive life is protective against breast cancer in women. The protective effects of parity have variously been attributed to the differentiation that accompanies pregnancy and lactation, alterations in ovarian hormone receptor levels, and altered sensitivity to ovarian hormones. Butyrate, a short-chain fatty acid, induces differentiation in breast cancer cell lines and decreases hormone receptor expression. Butyrate also inhibits proliferation in breast cancer cell lines and modulates expression of key cell cycle-regulatory proteins including cyclin D1. Given these properties, butyrate could be considered a promising agent for breast cancer prevention. Therefore, this study aimed to determine the effects of butyrate on normal human breast epithelial cells and to compare the effects of two stable butyrate derivatives with more favorable pharmacological properties: phenylacetate and its p.o. active precursor phenylbutyrate. Treatment with each agent resulted in concentration-dependent growth inhibition in a normal breast epithelial cell line and two breast cancer cell lines (MCF-7 and MDA-MB-231). Phenylbutyrate and butyrate inhibited proliferation to a similar extent, but phenylacetate was less effective in all of the cell lines. All three of the agents induced differentiation (accumulation of lipid droplets) in normal as well as in breast cancer cells and caused a decrease in estrogen receptor (ER) mRNA in MCF-7 cells. The butyrates decreased expression of cyclin D1, increased expression of p21^Waf1/Cip1, and hypophosphorylated pRB in the normal mammary epithelial cells. The effects on cyclin D1 expression correlated with the effects on cell proliferation, which suggests that modulation of cyclin D1 expression may underpin the antiproliferative effects of butyrates. We have shown that butyrate and butyrate-like agents are able to decrease proliferation and induce differentiation in normal breast cells as well as in malignant breast cells (ER-positive and ER-negative) and, as such, may be considered as candidate chemopreventative agents for women at high risk of developing breast cancer.

This article has been cited by other articles:

				K. E. Joung, K. N. Min, J. Y. An, D.-K. Kim, G. Kong, and Y. Y. Sheen Potent In vivo Anti-Breast Cancer Activity of IN-2001, a Novel Inhibitor of Histone Deacetylase, in MMTV/c-Neu Mice. Cancer Res., May 15, 2006; 66(10): 5394 - 5402. [Abstract] [Full Text] [PDF]

				N. Normanno, M. Di Maio, E. De Maio, A. De Luca, A. de Matteis, A. Giordano, F. Perrone, and on behalf of the NCI-Naples Breast Cancer Group Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer Endocr. Relat. Cancer, December 1, 2005; 12(4): 721 - 747. [Abstract] [Full Text] [PDF]

				D. C. Drummond, C. Marx, Z. Guo, G. Scott, C. Noble, D. Wang, M. Pallavicini, D. B. Kirpotin, and C. C. Benz Enhanced Pharmacodynamic and Antitumor Properties of a Histone Deacetylase Inhibitor Encapsulated in Liposomes or ErbB2-Targeted Immunoliposomes Clin. Cancer Res., May 1, 2005; 11(9): 3392 - 3401. [Abstract] [Full Text] [PDF]

				J. P. Alao, E. W-F. Lam, S. Ali, L. Buluwela, W. Bordogna, P. Lockey, R. Varshochi, A. V. Stavropoulou, R. C. Coombes, and D. M. Vigushin Histone Deacetylase Inhibitor Trichostatin A Represses Estrogen Receptor {alpha}-Dependent Transcription and Promotes Proteasomal Degradation of Cyclin D1 in Human Breast Carcinoma Cell Lines Clin. Cancer Res., December 1, 2004; 10(23): 8094 - 8104. [Abstract] [Full Text] [PDF]

				J. Gilbert, S. D. Gore, J. G. Herman, and M. A. Carducci The Clinical Application of Targeting Cancer through Histone Acetylation and Hypomethylation Clin. Cancer Res., July 15, 2004; 10(14): 4589 - 4596. [Abstract] [Full Text] [PDF]

				A Buda, D Qualtrough, M A Jepson, D Martines, C Paraskeva, and M Pignatelli Butyrate downregulates {alpha}2{beta}1 integrin: a possible role in the induction of apoptosis in colorectal cancer cell lines Gut, May 1, 2003; 52(5): 729 - 734. [Abstract] [Full Text]

				C. Kennedy, K. Byth, C. L. Clarke, and A. deFazio Cell Proliferation in the Normal Mouse Mammary Gland and Inhibition by Phenylbutyrate Mol. Cancer Ther., October 1, 2002; 1(12): 1025 - 1033. [Abstract] [Full Text] [PDF]

				P. N. Munster, T. Troso-Sandoval, N. Rosen, R. Rifkind, P. A. Marks, and V. M. Richon The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Induces Differentiation of Human Breast Cancer Cells Cancer Res., December 1, 2001; 61(23): 8492 - 8497. [Abstract] [Full Text] [PDF]

				A. Derjuga, C. Richard, M. Crosato, P. S. Wright, L. Chalifour, J. Valdez, A. Barraso, H. A. Crissman, W. Nishioka, E. M. Bradbury, et al. Expression of p21Waf1/Cip1 and Cyclin D1 Is Increased in Butyrate-resistant HeLa Cells J. Biol. Chem., October 5, 2001; 276(41): 37815 - 37820. [Abstract] [Full Text] [PDF]